Evidence map›Paper›PMID 38414646›Full record

ArticleBiology methods & protocols2024

Identification and quantitation of multiple variants in RNA virus genomes.

Johnny Sena, Lovkesh Karwal, Callum Bell, Nicholas Devitt, Faye Schilkey, Claire Huang, Jill Livengood, Subash Das, Hansi J Dean

Abstract read
In one paragraph

Article in Biology methods & protocols, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Johnny SenaNational Center for Genome Resources, Santa Fe, NM, United States.ORCID https://orcid.org/0000-0003-1846-8739
Lovkesh KarwalVaccine Business Unit, Takeda Pharmaceuticals, Cambridge, MA, United States.ORCID https://orcid.org/0009-0007-4486-220X
Callum BellNational Center for Genome Resources, Santa Fe, NM, United States.
Nicholas DevittNational Center for Genome Resources, Santa Fe, NM, United States.
Faye SchilkeyNational Center for Genome Resources, Santa Fe, NM, United States.
Claire HuangArboviral Diseases Branch, Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, CO, United States.
Jill LivengoodVaccine Business Unit, Takeda Pharmaceuticals, Cambridge, MA, United States.
Subash DasVaccine Business Unit, Takeda Pharmaceuticals, Cambridge, MA, United States.
Hansi J DeanVaccine Business Unit, Takeda Pharmaceuticals, Cambridge, MA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The goal of the study was to identify and characterize RNA virus variants containing mutations spread over genomic distances >5 kb. As proof of concept, high-quality viral RNA of the Dengue 2 component of Takeda's tetravalent dengue vaccine candidate (TDV-2) was used to develop a reverse transcription-polymerase chain reaction protocol to amplify a ∼5.3 kb cDNA segment that contains the three genetic determinants of TDV-2 attenuation. Unique molecular identifiers were incorporated into each viral cDNA molecule for PacBio library preparation to improve the quantitative precision of the observed variants at the attenuation loci. Following assay optimization, PacBio long-read sequencing was validated with multiple clone-derived TDV-2 revertant variants and four complex revertant mixtures containing various compositions of TDV-2 and revertant viruses. PacBio sequencing analysis correctly identified and quantified variant composition in all tested samples, demonstrating that TDV-2 revertants could be identified and characterized and supporting the use of this method in the differentiation and quantification of complex variants of other RNA viruses. Long-read sequencing can identify complex RNA virus variants containing multiple mutations on a single-genome molecule, which is useful for in-depth genetic stability and revertant detection of live-attenuated viral vaccines, as well as research in virus evolution to reveal mechanisms of immune evasion and host cell adaption.

Indexed as

dengue virusPacBioRNA virus variantUMIs

Identifiers

PMID38414646
PMCPMC10898329

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.